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Spinal cord injury is a debilitating injury that affects 12,000 people in the U.S. annually.
1
 
Current treatment is limited; research in tissue engineering, biomaterials, and gene therapy have 
dominated neuroregeneration studies. However, an inadequate amount of attention has been 
dedicated to the development of small molecule therapeutics. Vinaxanthone (SM-345431) and 
xanthofulvin (SM-216289) are two novel small molecule compounds co-isolated from 
Penicillium sp. SPF-3059 that demonstrate axonal regenerative properties in both C. elegans and 
adult rats. Initially, the molecules were thought to inhibit semaphorin 3A, a protein which 
induces the collapse of neuronal growth cones. Knockout studies of semaphorin 3A indicate that 
simply shutting off inhibitory signaling does not equate to the pronounced neuroregeneration 
present from vinaxanthone and xanthofulvin administration, suggesting that the molecules 
possess alternative modes of action. To uncover the mechanism of action for these two small 
molecules, analogs of vinaxanthone and xanthofulvin are being developed for structure-activity-
relationship studies in C. elegans. Further research into the action of these analogs will provide 
useful information regarding CNS inhibitory signaling in spinal cord injury models and potential 
therapeutic options. Currently, the synthesis of vinaxanthone analogs is being pursued. Initial 
data from G-protein coupled receptor assays (GPCR) indicates that various vinaxanthone analogs 
have been found to possess either positive or negative allosteric modulation for the succinate 
receptor 1 protein (SUCNR1 or GPR91). The synthesis of more vinaxanthone analogs will be 






















 Until the pioneer Albert Aguayo and his co-workers discovered that adult central nervous 
system (CNS) neurons could grow if offered a peripheral nerve transplant, scientists and 
physicians believed that neuroregeneration in the CNS was improbable, if not impossible. The 
inhibitory microenvironment of the CNS following injury prevents successful regeneration of 
neurons. Aguayo utilized the more flexible microenvironment of the peripheral nervous system 
through the creation of peripheral nerve grafts to promote neuroregeneration of CNS neurons.
2
  
Upon spinal cord injury (SCI), successive steps lead to the formation of a glial scar in 
which glial cells are recruited and surround the site of injury. These glial cells (mainly 
astrocytes) release proteins and chemical signals which prevent the elongation of axons and 
regeneration of neurons in the associated glial scar. Some of these inhibitory proteins include the 
semaphorin family of proteins.
5
 Semaphorin 3A (Sema3A) has been shown to promote human 
neuronal growth cone collapse and is thought to be a guidance cue for developing axons. 
Sema3A binds to plexin-neuropilin-1 complexes which leads to its inhibitory signaling.
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Successful Sema3A inhibitors were thought to be isolated from Penicillium sp. SPF-3059 by 
Kumagai et al.
6
 The inhibitors, xanthofulvin (1) and vinaxanthone (2), are exciting leads in 
axonal regeneration. Kaneko et al. published a study in Nature Medicine displaying the 
remarkable regenerative properties of xanthofulvin following complete spinal cord transection in 
adult rats, and Omoto et al. 
published a study showing the 
neuroregenerative properties of 
vinaxanthone in corneal 
transplantation experiments in mice models.
8,11
 However, genetic knockdown of Sema3A does 
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not garner the pronounced regenerative effects characteristic of xanthofulvin or vinaxanthone, 
suggesting that the mode of action for xanthofulvin and vinaxanthone (previously identified as 
Sema3A inhibitors) is unclear.
7
 Analog synthesis for vinaxanthone has been delineated by the 
Siegel group, and efforts are underway to synthesize these analogs. Structure-activity-relation 
and G-protein coupled receptor studies are being pursued upon synthesis of vinaxanthone 




 The first synthesis of vinaxanthone was performed by Tatsuta et al. through the 
intermolecular Diels-Alder (IMDA) reaction of two molecules of a protected vinyl ketone 
precursor made in 14 steps. The protected vinyl ketone was generated from vanillin and 
successive oxidation reactions that led to a vinyl iodide precursor, which was then cross-coupled 
with methyl vinyl ketone using Pd(OAc)2 to generate the protected vinyl ketone intermediate. 
IMDA between protected vinyl ketone molecules led to the formation of protected vinaxanthone 
which then underwent de-protection with AlCl3 in toluene at 110˚ C for 2 hours. This synthesis 
provided the first biomimetic pathway for vinaxanthone synthesis but produced a mix of 
products in the final IMDA reaction.
3
 The Siegel synthesis improved upon the Tatsuta synthesis, 







C]acetate metabolism studies, Zeeck et al. envisioned the biosynthesis of 
chaetocyclinone C (4) through a non-enzymatic, twofold aldol condensation of a polyketide 
intermediate and a highly reactive aldehyde intermediate.
4
 The similarity in structure between 
chaetocyclinone C (4) and vinaxanthone (2) motivated the Siegel group to pursue a dimerization 







Siegel First Generation Synthesis 
5,6-dehydropolivione (5) is synthesized from tetronic acid (6) in eight steps (Scheme 1). Tetronic 
acid (6) undergoes two protection steps, installing a pivaloyl (Piv) and tert-butyldimethylsillyl 
(TBS) group, to form furan (7). Furan (7) then undergoes a Diels-Alder reaction with keto ester 
(8) to form the desired bicyclic product (9) in a >20:1 ratio. Keto ester (8) is formed from 3-
butyn-2-ol (11) in 4 steps as indicated in Scheme 1 (for more detail, see Experimental section). 
Treatment with hydrochloric acid induces the bicyclic compound (9) to aromatize and produce 
acetophenone (13) with migration of the pivaloyl group. The free hydroxyl group from the 
acetophenone (13) is then protected to generate (14). The enaminone (15) is then produced by 
using the dimethyl acetal of dimethylformamide in dimethoxyethane at elevated temperatures, 
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simultaneously cleaving the TBS group. Formation of protected 5,6-dehydropolivione (17) 
occurs through treatment of enaminone (15) with 5-acetyl Meldrum’s acid (16) in refluxing 
toluene, yielding the protected 5,6-dehydropolivione (17) in 42 % yield. Cleavage of all 
protecting groups is achieved with boron trichloride in dichloromethane at room temperature, 
generating 5,6-dehydropolivione (5). Vinaxanthone (2) was then produced by heating 5,6-
dehydropolivione (5) in deionized water to 55˚ C at 61 % yield.
10
  




Siegel Second Generation Synthesis 
While developing the xanthofulvin synthesis, the Siegel group discovered an alternative 
synthesis of vinaxanthone through the aldol condensation of an ynone (19) and reactive aldehyde 
(20) (Scheme 2), similar to Zeeck’s proposal. It was discovered that in the presence of wet 
acetonitrile and triethylamine, the ynone intermediate (19) used in the xanthofulvin synthesis 
would dimerize to form protected vinaxanthone. The proposed mechanism for the dimerization is 
highlighted in Scheme 3. In order to produce the ynone intermediate, the enaminone species (15) 
from the original synthesis cyclizes with iodine in chloroform to generate the iodochromone 
species (18). The iodochromone (18) then undergoes a Sonagashira cross-coupling reaction with 
3-butyn-2-ol (11) to generate a propargyl alcohol species. The alcohol is then oxidized to the 
ynone species (19) with pyridinium dichlorochromate (PDC). Placing the ynone (19) in 
acetonitrile and water (1000 equivalents of H2O) with .5 eq. of triethylamine at room temperature 
generated the protected vinaxanthone product at 87 % yield through formation of a highly 
reactive aldehyde species (20). The protected vinaxantone is then deprotected through the use of 











Scheme 2: De novo synthesis of vinaxanthone 
 







The synthesis of vinaxanthone through the ynone precursor introduces more steps; however, it 
allows for the synthesis of diverse analogs since different combinations of ynone intermediates 
8 
 
may undergo cycloaddition. The Siegel group envisions 8 alternative ynone intermediate species, 
which leads to 64 possible analogs of vinaxanthone (Figure 1).  




 Initially, 3 different ynone subunits were synthesized to form several different 
vinaxanthone analog species. The following ynones were formed: 
    
      19       21     22 
The formation of ynone (19) proceeded through the scheme shown above in Scheme 2 and below 
in Scheme 4. Ynone (22) was formed through a similar pathway as ynone (19) (Scheme 4); 2,4-
dihydroxyacetophenone (23)  was used as the initial starting material instead of forming a 
9 
 
hydroxyacetophenone intermediate from tetronic acid. The protection of 2,4-
dihydroxyacteophenone (23) using chloromethyl methyl ether yielded an acetophenone 
intermediate (24) in 69 % yield. Enaminone and subsequent iodochromone (25) formation 
following procedures previously established yielded the mono-substituted iodochromone (25) in 
78 % yield over two steps. Sonagashira cross-coupling with commercially available 3-butyn-2-ol 
(11) and subsequent oxidation using PDC yielded the desired ynone (22) in 36 % over two steps. 
Ynone (21) was generated from veratraldehyde (26). Veratraldehyde (26) was reduced to an 
alcohol using H2O2 and formic acid, and subsequently acylated with boron trifluoride and acetic 
anhydride to form intermediate (27). The phenol (27) underwent enaminone and iodochromone 
formation as described previously. Removal of the methoxy groups was achieved using boron 
tribromide in dichloromethane at 0˚ C to generate a catechol. The catechol species was protected 
to generate the dimethoxy methyl protected iodochromone (28). Iodochromone (28) underwent 
Songashira crosss-coupling with 3-butyn-2-ol (11) and oxidation with PDC to generate ynone 
(21).  




Ynones (19, 21, 22) were combined to form 9 different analogs of vinaxanthone 
(including the original vinaxanthone molecule) displayed in Figure 2. The general procedure for 
combining two ynone analogs is highlighted in Scheme 5. The intial ynone placed in wet 
acetonitrile (1000 eq. of H2O) equilibrates to the highly reactive aldehyde intermediate and reacts 
with subsequent addition of the second ynone. The initial ynone forms the left side of the 
vinaxanthone product, while the second ynone forms the right side of the vinaxanthone product. 
Multiple vinaxanthone analog products are formed, unless the same ynone intermediates are used 
for the dimerization reaction. The desired vinaxanthone analog was purified by column 
chromatography using a 5:2:1 dichloromethane:ethyl acetae:hexanes solution. 
  The dimerization reaction yields are displayed in Figure 2 for various combinations of 
ynones (for specific procedures, see Experimental section); the yields displayed in parenthesis 
indicate formation of other vinaxanthone analog products.  All protected vinaxanthone analogs 
(2a, 2b, 2c, 2f) generated with ynone (19) underwent de-protection by stirring in boron 
trichloride in dichloromethane for 1 hour; the protected vinaxanthone analogs (2d, 2e, 2g, 2h) 
that did not use ynone (19) for any part of the dimerization reaction underwent de-protection 
through a slightly altered procedure by stirring in methanolic HCl for 8 hours. All of the de-
protection reactions yielded the desired vinaxanthone analog at about 90 % yield or better. 








 9 vinaxanthone analogs (including the original vinaxanthone molecule) were formed and 
analyzed through GPCR screening from Millipore Co. Millipore Co. identified that vinaxanthone 
was an allosteric modulator for GPR91 or succinate receptor 1. The vinaxanthone analogs 
displayed a mix of positive and negative modulation of GPR91 as indicated in Figure 2. Analog 
(2a) displays enhanced positive allosteric modulation of GPR91 as compared to vinaxanthone 





 fluorescence absorbance signals generated from the activity of GPCRs (a 
value of 0 indicates no allosteric modulation).  
GPR91 enhances angiogenesis of blood vessels during hypoxic conditions.
12,13
 The 
interplay between angiogenesis and neurogenesis is being further studied; common signaling 
pathways exist in the development of the nervous and circulatory systems.
12
 Synthesis of the 
remaining ynone intermediates will allow experimentation on 64 analogs. Further data collection 
will be pursued regarding the activity of the proposed 64 analogs and structure-activity-
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All reactions were performed in flame dried round bottom or modified Schlenk (Kjedahl 
shape) flasks fitted with rubber septa under a positive pressure of argon, unless otherwise 
indicated. Air-and moisture-sensitive liquids and solutions were transferred via syringe or 
canula. Organic solutions were concentrated by rotary evaporation at 20 torr. Methylene chloride 
(CH2Cl2) and tetrahydrofuran (THF) were purified using a Pure-Solv MD-5 Solvent Purification 
System (Innovative Technology).  Acetonitrile (MeCN) was purified using a Vac 103991 
Solvent Purification System (Vacuum Atmospheres). Dimethoxyethane (DME) was purchased 
from Acros (99+%, stabilized with BHT), methanol (MeOH) was purchased from Sigma-Aldrich 
(99.8%, anhydrous), ethanol (EtOH) was purchased from Pharmco-Aaper (200 proof, absolute).  
All other reagents were used directly from the supplier without further purification unless noted.  
Analytical thin-layer chromatography (TLC) was carried out using 0.2 mm commercial silica gel 
plates (silica gel 60, F254, EMD chemical) and visualized using a UV lamp and/or aqueous ceric 
ammonium molybdate (CAM) or aqueous potassium permanganate (KMnO4) stain.  Infrared 
spectra were recorded on a Nicolet 380 FTIR using neat thin film or KBr pellet technique.  High-
resolution mass spectra (HRMS) were recorded on a Karatos MS9 and are reported as m/z 





or [M-H].  Nuclear magnetic resonance spectra (
1
H NMR and 
13
C NMR) were recorded with a 
Varian Gemini [(400 MHz, 
1
H at 400 MHz, 
13
C at 100 MHz), (500 MHz, 
13
C at 125 MHz), (600 
MHz, 
13
C at 150 MHz)].  For CDCl3 solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvent; CHCl3 δ H (7.26 ppm) and 
CDCl3 δ D (77.0 ppm).  For (CD3)2SO solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvents; (CD3)(CHD2)SO δ H 
(2.50 ppm) or (CD3)2SO δ C (39.5 ppm). Coupling constants are reported in Hertz (Hz).  Data for 
1
H-NMR spectra are reported as follows: chemical shift (ppm, referenced to protium; s = singlet, 
d = doublet, t = triplet, q= quartet, dd = doublet of doublets, td = triplet of doublets, ddd = 
doublet of doublet of doublets, m = multiplet, coupling constant (Hz), and integration). Melting 




To a stirred solution of tetronic acid (6) (25.0 g, 250 mmol, 1.0 equiv.), 4-
dimethylaminopyridine (1.53 g, 12.5 mmol, 0.05 equiv.) and N,N-diisopropylethylamine (45.8 
mL, 262 mmol, 1.05 equiv.) in CH2Cl2 (500 mL, 0.5 M) at 0 °C was added neat pivaloyl chloride 
(25.9 mL, 262 mmol, 1.05 equiv.) dropwise over 40 minutes. Upon complete addition the 
reaction mixture was allowed to warm to 23 °C. After 16 hours, the reaction mixture was 
concentrated in vacuo to give an amber oil. The oil was dissolved in Et2O (500 mL) and washed 
with H2O (500 mL). The aqueous layer was extracted with Et2O (5 x 500 mL) and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give tetronate X (41.0 g, 223 




Rf = 0.60 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 6.00 (t, J = 1.4 Hz, 
1H), 4.91 (d, J = 1.4 Hz, 2H), 1.32 (s, 9H); 
13
C NMR (100 MHz, CDCl3): δ 173.2, 172.2, 169.1, 
100.2, 68.2, 38.3, 26.4; IR (film, υ cm 
-1
): 1779, 1746, 1072. 
 
 
5-((tert-butyldimethylsilyl)oxy)furan-3-yl pivalate (7) 
To a stirred solution of tetronate (30.0 g, 163 mmol, 1.0 equiv.) and triethylamine (29.8 
mL, 212 mmol, 1.3 equiv.) in CH2Cl2 (226 mL, 0.72 M) at 0 °C was added neat tert-
butyldimethylsilyl triflate (37.8 mL, 165 mmol, 1.01 equiv.) dropwise over 10 minutes. Upon 
complete addition the reaction mixture was allowed to warm to 23 °C. After 1 hour, the reaction 
mixture was concentrated in vacuo to give an amber oil. The oil was suspended in pentane (200 
mL) and stirred for 1 hour at 23 °C. The organic layer was decanted and washed with sat. aq. 
NaHCO3 (3 x 100 mL), H2O (100 mL) and brine (100 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give furan X (37.9 g, 127 mmol, 78%) as an amber oil. 
 
Rf = 0.55 (silica gel, 20:1 hexanes:EtOAc); 
1
H NMR (300 MHz, CDCl3): δ 7.10 (d, J = 1.2 Hz, 
1H), 5.15 (d, J = 1.2 Hz, 1H), 1.29 (s, 9H), 0.96 (s, 9H), 0.24 (s, 6H); 
13
C NMR (100 MHz, 
CDCl3): δ 175.3, 154.3, 139.4, 120.6, 80.1, 39.0, 27.1, 25.4, 18.0, -4.85; IR (film, υ cm 
-1
): 3202, 
3141, 1753, 1627; HRMS (ESI) calc. for C15H27O4Si [M+H]
+




To a stirred solution of 3-butyn-2-ol (11) (100 g, 1.43 mol, 1.0 equiv.) and ethyl vinyl 
ether (151 mL, 1.57 mol, 1.1 equiv.) in CH2Cl2 (3 L, 0.48 M) at 23 °C was added solid 
pyridinium p-toluenesulfonate (35.9 g, 143 mmol, 0.1 equiv.). After 1 hour, the reaction mixture 
was diluted with Et2O (1 L) and washed with brine (2 L). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give a mixture of diastereomeric alkynes (201 g, 1.41 mol, 
99%) as a clear amber oil. 
 
Rf = 0.40 (silica gel, 1:1 hexanes:EtOAc);
 1
H NMR (400 MHz, CDCl3): δ 4.96 (q, J = 5.5 Hz, 
1H), 4.85 (q, J = 5.5 Hz, 1H), 4.50 (q, J = 6.7 Hz, 1H), 4.35 (q, J = 6.7 Hz, 1H), 3.75 (m, 1H), 
3.62 (m, 1H), 3.53 (m, 2H), 2.40 (s, 1H), 2.39 (s, 1H), 1.46 (d, J = 3.1 Hz, 3H), 1.44 (d, J = 3.1 
Hz, 3H), 1.35 (d, J = 2.7 Hz, 3H), 1.34 (d, J = 2.7 Hz, 3H), 1.21 (t, J = 7.0 Hz, 6H); 
13
C NMR 
(100 MHz, CDCl3): δ 98.5, 97.5, 84.5, 83.6, 72.4, 72.0, 61.1, 60.5, 60.0, 59.9, 22.3, 21.9, 20.0, 
19.9, 15.2, 14.9; HRMS (EC-CI) calc. for C8H13O2 [M+H]
+
: 141.0916, obs. 141.0918. 
 
 
tert-butyl 4-(1-ethoxyethoxy)pent-2-ynoate (12) 
To a stirred solution of diasteromeric alkynes (110 g, 774 mmol, 1.0 equiv.) in THF (4.5 
L, 0.17 M) at −78 °C was added a 2.0 M solution of n-butyllithium in hexanes (404 mL, 808 
mmol, 1.05 equiv.). After 15 minutes, neat di-tert-butyl dicarbonate (186 mL, 808 mmol, 1.05 
16 
 
equiv.) was added over 10 minutes. Upon complete addition the reaction mixture was allowed to 
warm to 23 °C. The reaction mixture was diluted with Et2O (1.5 L) and washed with H2O (3 L) 
and brine (3 L). The organic layer was dried over MgSO4 and concentrated in vacuo to give a 
mixture of diastereomeric esters (12) (180 g, 743 mmol, 96%) as an amber oil. 
 
Rf = 0.21 (silica gel, 20:1 hexanes:EtOAc);
 1
H NMR (400 MHz, CDCl3): δ 4.91 (q, J = 5.1 Hz, 
1H), 4.82 (q, J = 5.1 Hz, 1H), 4.56 (q, J = 6.8 Hz, 1H), 4.40 (q, J = 6.8 Hz, 1H), 3.73 (m, 1H), 
3.62 (m, 1H), 3.56 (m, 1H), 3.50 (m, 1H), 1.49 (s, 18 H), 1.46 (d, J = 1.7 Hz, 6H), 1.34 (d, J = 
1.4 Hz, 6H) 1.12 (t, J = 8.5 Hz, 6H); 
13
C NMR (100 MHz, C6D6): δ 152.6, 152.5, 99.3, 98.3, 
86.1, 85.2, 82.9, 82.7, 78.3, 77.9, 61.0, 60.4, 60.3, 60.2, 27.8 (2 signals), 21.8, 21.5, 20.1, 20.0, 
15.5, 15.3; IR (film, υ cm 
-1
): 1710, 1274, 1160;  HRMS (ESI) calc. for C13H22NaO4 [M+Na]
+
: 




To a stirred solution of diasteromeric esters (12) (117 g, 483 mmol, 1.0 equiv.) in EtOH 
(4.8 L, 0.1 M) at 78 °C was added solid pyridinium p-toluenesulfonate (12.1 g, 48.3 mmol, 0.1 
equiv.). After 2 hours, the reaction mixture was allowed to cool to 23 °C. The reaction mixture 
was diluted with Et2O (2.4 L) and washed with brine (4 L). The organic layer was dried over 
MgSO4 and concentrated in vacuo to give alcohol X (73.1 g, 429 mmol, 89%) as an amber oil. 
 
Rf = 0.30 (silica gel, 3:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 4.62 (m, 1H), 2.13 (s, 
1H), 1.51 (m, 12H); 
13
C NMR (100 MHz, CDCl3): δ 152.8, 86.8, 82.9, 77.5, 57.8, 27.8, 23.1; IR 
(film, υ cm 
-1
): 3400, 1709; HRMS (EC-CI) calc. for C9H15O3 [M+H]
+




tert-butyl 4-oxopent-2-ynoate (8) 
To a stirred solution of alcohol (73.0 g, 429 mmol, 1.0 equiv.) in Me2CO (1.2 L, 0.43 M) 
at 0 °C was slowly added ice-cold 1.53 M (67.0 g CrO3, 58.0 mL conc. H2SO4 and 160 mL H2O) 
Jones reagent (280 mL, 429 mmol, 1.0 equiv.) over 15 mintues. After 30 minutes, i-PrOH (40 
mL) was added to neutralize any excess Jones reagent and the reaction mixture was diluted with 
CH2Cl2 (1 L). The orangic layer was decanted and washed with H2O (1 L), sat. aq. NaHCO3 (1 
L) and brine (1 L). The organic layer was dried over Na2SO4 and concentrated in vacuo to give 
keto ester X (57.5 g, 342 mmol, 80%) as a clear amber oil. 
 
Rf = 0.40 (silica gel, 10:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 2.41 (s, 3H), 1.52 (s, 
9H); 
13
C NMR (100 MHz, CDCl3): δ 182.8, 151.0, 85.4, 79.2, 79.0, 32.3, 27.9; IR (film, υ cm 
-
1
): 1716, 1689; HRMS (EC-CI) calc. for C9H13O3 [M+H]
+








To a stirred solution of furan (7) (70.4 g, 236 mmol, 1.0 equiv.) in THF (212 mL, 1.1 M) 
at 0 °C was added keto ester (8) (39.7 g, 236 mmol, 1.0 equiv.). Upon complete addition 
the reaction mixture was allowed to warm to 23 °C. After 1 hour, the reaction mixture was 
concentrated in vacuo to give bicycle (9) (110 g, 236 mmol, yield taken after subsequent step) in 
> 20:1 regioselectivity as a viscous burgundy oil. 
 
Rf = 0.35 (silica gel, 10:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 6.38 (s, 1H), 5.24 (s, 
1H), 2.43 (s, 3H), 1.47 (s, 9H), 1.25 (s, 9H), 0.90 (s, 9H), 0.20 (s, 3H), 0.18 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3): δ 199.3, 174.3, 167.7, 163.7, 161.2, 146.3, 118.5, 113.9, 82.3, 78.2, 39.2, 
30.7, 27.9, 26.8, 25.4, 17.7, -3.5, -3.7; IR (film, υ cm 
-1
): 1769, 1712; HRMS (EC-CI) calc. for 
C24H38O7Si [M+Na]
+
: 489.22790, obs. 489.22801. 
 
 
tert-butyl 2-acetyl-3-((tert-butyldimethlsilyl)oxy)-5-hydroxy-6-(pivaloyloxy)benzoate (13) 
To a stirred solution of bicycle (9) (110 g, 236 mmol, 1.0 equiv.) in THF (471 mL, 0.5 
M) at 0 °C was slowl added a 4.0 M solution of hydrochloric acid in dioxane (47.1 mL, 47.1 
mmol, 0.2 
equiv.) over 5 minutes. Upon complete addition the reaction mixture was allowed to warm to 23 
°C. After 2 hours, the reaction mixture was concentrated in vacuo to give an amber oil. The 
crude material was purified via silica gel column chromatography (20:1 hexanes:EtOAc) to give 
pure phenol X (82.9 g, 178 mmol, 75% over 2-steps) as a clear light-yellow oil. 
 
Rf = 0.38 (silica gel, 10:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 10.91 (s, 1H), 6.71 
(s, 1H), 2.48 (s, 3H), 1.54 (s, 9H), 1.38 (s, 9H), 0.94 (s, 9H), 0.18 (s, 9H); 
13
C NMR (100 MHz, 
CDCl3): δ 202.3, 176.3, 168.4, 148.7, 142.5, 139.7, 131.9, 119.9, 111.0, 85.7, 39.2, 32.5, 27.8, 
27.2, 25.5, 18.0, -4.4; IR (film, υ cm 
-1
): 1763, 1716, 1673; HRMS (EC-CI) calc. for C24H38O7Si 
[M+Na]
+
: 489.22790, obs. 489.22813. 
 
General Procedure for Methoxymethyl Ether Protection 
 To a stirred solution of phenol (1.0 equiv.) and N,N-diisopropylethylamine (1.5 equiv.) in 
CH2Cl2 (0.2 M) at 0 °C was added and a 2.1 M solution of methoxymethyl chloride in 
PhMe/MeOAc (1.5 equiv.). After 1 hour, the reaction mixture was diluted with 0.1 M aq. HCl 
and extracted with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo to give crude methoxymethyl ether. The crude material was purified via 









 Following the general procedure for methoxymethyl ether protection, phenol (13) was 
transformed into methoxymethyl ether (14). The crude material was purified via silica gel 
column chromatography (10:1 hexanes:EtOAc) to give pure methoxymethyl ether (14) (61.4 g, 
120 mmol, 68%) as a white solid (m.p. 60-62 °C).  
 
Rf = 0.61 (silica gel, 3:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 6.76 (s, 1H), 5.10 (s, 
2H), 3.42 (s, 3H), 2.54 (s, 3H), 1.49 (s, 9H), 1.34 (s, 9H), 0.97 (s, 9H), 0.21 (s, 9H); 
13
C NMR 
(100 MHz, CDCl3): δ 200.9, 175.7, 163.5, 150.9, 150.4, 132.8, 128.1, 125.7, 108.6, 94.6, 82.5, 
55.9, 38.9, 31.7, 27.7, 27.1, 25.6, 18.1, -4.4; IR (film, υ cm 
-1
): 1761, 1733, 1703; HRMS (ESI) 
calc. for C26H42NaO8Si [M+Na]
+




Following the general procedure for methoxymethyl ether protection, 2’,4’-
dihydroxyacetophenone (23) was transformed into methoxymethyl ether (24). The crude material 
was purified via silica gel column chromatography (10:1 hexanes:EtOAc) to give pure 
methoxymethyl ether (24) (8.84 g, 45.1 mmol, 69%) as a clear oil. 
 
Rf = 0.45 (silica gel, 5:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 12.62 (s, 1H), 7.66 (d, 
J = 8.9 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.55 (dd, J = 8.9, 2.4 Hz, 1H), 5.21 (s, 2H), 3.48 (s, 
3H), 2.57 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 202.7, 164.7, 163.5, 132.4, 114.6, 108.1, 
103.6, 93.9, 56.3, 26.1; IR (film, υ cm
-1
): 3406, 1635, 1244, 991; HRMS (EC-CI) calc. for 
C10H13O4 [M+H]
+




To a stirred solution of 3,4-dimethoxybenzaldehyde (26) (30.0 g, 181 mmol, 1.0 equiv.) 
in CH2Cl2 (361 mL, 0.5 M) at 23 °C was added 30% aq. H2O2 (46.1 mL, 451 mmol, 2.5 equiv.) 
and formic acid (27.7 mL, 722 mmol, 4.0 equiv.). The reaction mixture was stirred at 40 °C for 
42.5 hours. The reaction mixture was then cooled to 23 °C and the organic layer was separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 50 mL) and the combined organic layers were 
dried over Na2SO4 and concentrated in vacuo to about 361 mL (0.5 M). 5 M aq. NaOH (251 mL, 
1.26 mol, 10 equiv.) was then slowly added and the reaction mixture was stirred at 23 °C for 20 
minutes. The organic layer was separated and the aqueous layer was washed with CH2Cl2 (3 x 
100 mL). The aqueous layer was acidified to pH = 1.0 with conc. HCl and extracted with CH2Cl2 
(3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo 




Rf = 0.43 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 6.71 (d, J = 8.4 Hz, 
1H), 6.46 (d, J = 2.7 Hz, 1H), 6.35 (dd, J = 8.4, 2.7 Hz, 1H), 5.93 (bs, 1H), 3.79 (s, 3H), 3.76 (s, 
3H); 
13
C NMR (100 MHz, CDCl3): δ 150.2, 149.7, 142.8, 112.5, 105.9, 100.6, 56.5, 55.6; IR 
(film, υ cm
-1
): 3382, 1513, 1223; HRMS (EC-CI) calc. for C8H11O3 [M+H]
+





To a stirred solution of 3,4-dimethoxyphenol (3.0 g, 19.5 mmol, 1 equiv.) in acetic 
anhydride (9.75 mL, 103 mmol, 5.3 equiv.) at 0 °C was added neat boron trifluoride diethyl 
etherate (4.8 mL, 38.9 mmol, 2 equiv.). The reaction mixture was stirred at 90 °C for 1 hour and 
then allowed to sit at 23 °C for 16 hours. The precipitate was collected and recrystallized from 
EtOH to give pure hydroxyacetophenone (27) (3.38 g, 17.7 mmol, 89%) as white needles (m.p. 
104-105 °C). 
 
Rf = 0.58 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 12.65 (s, 1H), 7.05 (s, 
1H), 6.46 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.56 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 202.0, 
160.0, 156.7, 141.8, 111.6, 111.5, 100.5, 56.6, 56.1, 26.3; IR (film, υ cm
-1
): 1632, 1511, 1265, 
1160, 1063; HRMS (EC-CI) calc. for C10H13O4 [M+H]
+





 Following the general procedure for methoxymethyl ether protection, catechol was 
transformed into iodochromone (28). In this case, 3.0 equivalents of N,N-diisopropylethylamine 
and 3.0 equivalents fo methoxymethyl chloride were used. The crude material was purified via 
silica gel column chromatography (2:1 hexanes:EtOAc) to give pure methoxymethyl ether (28) 
(417 mg, 1.06 mmol, 71%) as a white solid (m.p. 105-106 °C). 
 
Rf = 0.29 (silica gel, 2:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.19 (s, 1H), 7.79 (s, 
1H), 7.17 (s, 1H), 5.31 (s, 2H), 5.27 (s, 2H), 3.50 (s, 3H), 3.48 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3): δ 172.2, 157.0, 152.7, 152.4, 145.5, 116.0, 110.8, 103.5, 95.4, 95.1, 86.3, 56.5, 56.3; IR 
(film, υ cm
-1
): 1617, 1453, 1284, 1152, 1041; HRMS (ESI) calc. for C13H13INaO6 [M+Na]
+
: 
414.96490, obs. 414.96555. 
 
General Procedure for Enaminone Formation 
To a stirred solution of hydroxyacetophenone (1.0 equiv.) in dimethoxyethane (0.5 M) at 
85 °C was added N,N-dimethylformamide dimethyl acetal (3.0 equiv.). After 4 hours, the 
reaction mixture was cooled to 23 °C and then concentrated in vacuo to give crude enaminone of 







Following the general procedure for enaminone formation, acetophenone (14) was 
transformed into enaminone (15) (yield taken after subsequent step), an orange solid (m.p. 118-
119 °C) of sufficient purity for subsequent reactions. 
 
Rf = 0.26 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 12.43 (bs, 1H), 7.77 
(d, J = 12 Hz, 1H), 6.70 (s, 1H), 5.49 (d, J = 12 Hz, 1H), 5.13 (s, 2H), 3.41 (s, 3H), 3.15 (s, 3H), 
2.84 (s, 3H), 1.47 (s, 9H), 1.34 (s, 9H); 
13
C NMR (100 MHz, CDCl3): δ 189.4, 175.8, 165.6, 
159.3, 154.4, 151.6, 130.1, 128.5, 113.7, 104.0, 95.2, 94.0, 82.4, 56.0, 45.1, 38.7, 37.1, 27.6, 
27.0; IR (film, υ cm 
-1
): 1751, 1716, 1632, 1111; HRMS (ESI) calc. for C23H33NNaO8 [M+Na]
+
: 




Following the general procedure for enaminone formation, acetophenone (27) was 
transformed into enaminone (yield taken after subsequent step), a yellow solid (m.p. 157-158 °C) 
of sufficient purity for subsequent reactions. 
 
Rf = 0.18 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (600 MHz, CDCl3): δ 14.25 (bs, 1H), 7.84 
(d, J = 12 Hz, 1H), 7.10 (s, 1H), 6.44 (s, 1H), 5.60 (d, J = 12 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 
3.16 (bs, 3H), 2.96 (bs, 3H); 
13
C NMR (150 MHz, CDCl3): δ 190.3, 160.1, 155.0, 154.1, 141.2, 
111.7, 111.1, 100.8, 89.7, 57.1, 55.9, 45.3, 37.3; IR (film, υ cm
-1
): 1630, 1543, 1376, 1228, 
1113; HRMS (ESI) calc. for C13H18NO4 [M+H]
+




Following the general procedure for enaminone formation, acetophenone (24) was 
transformed into enaminone (yield taken after subsequent step), a yellow solid (m.p. 95-96 °C) 
of sufficient purity for subsequent reactions. 
 
Rf = 0.25 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 7.85 (d, J = 12 Hz, 
1H), 7.62 (d, J = 8.9 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 6.48 (dd, J = 8.9, 2.4 Hz, 1H), 5.69 (d, J 
= 12 Hz, 1H), 5.19 (s, 2H), 3.47 (s, 3H), 3.18 (bs, 3H), 2.96 (bs, 3H); 
13
C NMR (100 MHz, 
CDCl3): δ 190.4, 165.0, 161.6, 154.1, 129.6, 114.8, 106.9, 103.8, 93.9, 89.6, 56.1, 45.2, 37.2; IR 
(film, υ cm
-1
): 1627, 1535, 1235, 1108; HRMS (ESI) calc. for C13H17NNaO4 [M+Na]
+
: 
274.10498, obs. 274.10491. 
 
General Procedure for Iodochromone Formation 
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To a stirred solution of crude enaminone (1.0 equiv.) in CHCl3 (0.1 M) at 23 °C was 
added solid iodine (2.0 equiv.). After 1 hour, the reaction mixture was diluted with sat. aq. 
Na2S2O3 and extracted with CH2Cl2. The organic layer was dried over Na2SO4 and concentrated 
in vacuo to give crude enaminone.  The crude material was purified via silica gel column 





 Following the general procedure for iodochromone formation, enaminone (15) was 
transformed into iodochromone (18). The crude material was purified via silica gel column 
chromatography (1:1 hexanes:EtOAc) to give pure iodochromone (18) (9.65 g, 18.1 mmol, 60% 
over 2-steps) as a white solid (m.p. 189-190 °C). 
 
Rf = 0.32 (silica gel, 3:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.19 (s, 1H), 7.17 (s, 
1H), 5.23, (s, 2H), 3.25 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 
13
C NMR (100 MHz, CDCl3): δ 
175.4, 170.9, 163.2, 156.8, 154.9, 153.3, 136.5, 128.3, 112.8, 103.5, 94.7, 86.7, 83.3, 56.6, 39.2, 
28.2, 27.2; IR (film, υ cm 
-1
): 1764, 1731, 1650; HRMS (ESI) calc. for C21H25INaO8 [M+Na]
+
: 




Following the general procedure for iodochromone formation, enaminone ((E)-3-
(dimethylamino)-1-(2-hydroxy-4,5-(dimethoxyphenyl)prop-2-en-1-one) was transformed into 
the iodochromone. The crude material was purified via silica gel column chromatography (2:1 
hexanes:EtOAc) to give pure iodochromone (7.01 g, 21.1 mmol, 35% over 2-steps) as a white 
solid (m.p. 170-172 °C). 
 
Rf = 0.32 (silica gel, 2:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 7.55 (s, 
1H), 6.86 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 172.2, 156.7, 
154.5, 152.1, 147.9, 115.0, 104.8, 99.3, 86.4, 56.4, 56.3; IR (film, υ cm
-1
): 1615, 1505, 1471, 
1289, 1226; HRMS (ESI) calc. for C11H9INaO4 [M+Na]
+




 To a stirred solution of iodochromone (3-iodo-6,7-dimethoxy-4H-chromen-4-one) (500 
mg, 1.51 mmol, 1.0 equiv.) in CH2Cl2 (15.1 mL, 0.1 M) at 0 °C was slowly added neat boron 
tribromide (0.86 mL, 9.03 mmol, 6.0 equiv.). The reaction mixture was stirred at 23 °C for 1.5 
hours. The reaction mixture was then carefully quenched with 1.25 M methanolic HCl (1.2 mL, 
2.08 mmol, 1.0 equiv.) at 0 °C and stirred for 5 minutes. The reaction mixture was purged with 
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N2 and concentrated in vacuo to give the iodochromone (458 mg, 1.51 mmol, 99%) as a grey 
solid (m.p. 215 °C (decomp.)) of sufficient purity for subsequent reactions. 
 
Rf = 0.72 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, CD3OD): δ 8.49 (s, 1H), 7.40 (s, 
1H), 6.89 (s, 1H); 
13
C NMR (100 MHz, CD3OD): δ 174.8, 159.6, 154.5, 153.4, 146.6, 115.6, 
108.9, 103.5, 85.4; IR (KBr, υ cm
-1
): 3218, 1616, 1471, 1308; HRMS (EC-CI) calc. for C9H6O4 
[M+H]
+




Following the general procedure for iodochromone formation, enaminone ((E)-3-
(dimethylamino)-1-(2-hydroxy-4-(methoxymethoxy)phenyl)prop-2-en-1-one) was 
transformed into iodochromone (25). The crude material was purified via silica gel column 
chromatography (3:1 hexanes:EtOAc) to give pure iodochromone (25) (11.69 g, 35.2 mmol, 78% 
over 2-steps) as a white solid (m.p. 101-102 °C). 
 
Rf = 0.28 (silica gel, 5:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.23 (s, 1H), 8.17 (d, J 
= 8.6 Hz, 1H), 7.10 (dd, J = 8.9, 2.4 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 5.27 (s, 2H), 3.50 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 172.4, 161.6, 157.4, 157.2, 127.8, 116.2, 116.1, 102.8, 94.2, 
86.9, 56.4; IR (film, υ cm
-1
): 1646, 1624, 1149; HRMS (ESI) calc. for C11H9INaO4 [M+Na]
+
: 
354.94377, obs. 354.94436. 
 
General Procedure for Propargyl Alcohol Formation 
To a stirred solution of iodochromone (1.0 equiv.), bis(triphenylphosphine) palladium (II) 
dichloride (0.02 equiv.) and copper (I) iodide (0.1 equiv.) in freeze pump thawed THF (0.1 M) at 
23 °C was added 3-butyn-2-ol (11) (4.0 equiv.). Diisopropylamine (3.0 equiv.) was then added.  
After 1 hour, the reaction mixture was diluted with pH = 7.0 phosphate buffer and extracted with 
CH2Cl2. The organic layer was dried over Na2SO4 and concentrated in vacuo to give crude 
propargyl alcohol.  The crude material was purified via silica gel column chromatography to give 





 Following the general procedure for propargyl alcohol formation, iodochromone (18) was 
transformed into the propargyl alcohol. The crude material was purified via silica gel column 
chromatography (1:1 hexanes:EtOAc) to give pure propargyl alcohol (1.71 g, 3.60 mmol, 64%) 
as a tan solid (m.p. 132-134 °C). 
 
Rf = 0.21 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.03 (s, 1H), 7.14 (s, 
1H), 5.21 (s, 2H), 4.75 (q, J = 6.7 Hz, 1H), 3.43 (s, 3H), 3.20 (bs, 1H), 1.63 (s, 9H), 1.51 (d, J = 
6.7 Hz, 3H);
 13
C NMR (100 MHz, CDCl3): δ 175.5, 173.3, 163.3, 157.5, 154.6, 153.2, 136.3, 
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128.1, 114.5, 110.5, 103.8, 97.5, 94.6, 83.2, 73.8, 58.6, 56.6, 39.2, 28.2, 27.2, 23.8; IR (film, υ 
cm
-1







Following the general procedure for propargyl alcohol formation, iodochromone (28) was 
transformed into propargyl alcohol. The crude material was purified via silica gel column 
chromatography (1:1 to 1:2 hexanes:EtOAc) to give pure propargyl alcohol (970 mg, 2.90 mmol, 
81%) as an amber oil. 
 
Rf = 0.12 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.82 (s, 
1H), 7.20 (s, 1H), 5.33 (s, 2H), 5.30 (s, 2H), 4.79 (q, J = 6.7 Hz, 1H), 3.52 (s, 3H), 3.51 (s, 3H), 
3.30 (bs, 1H), 1.54 (d, J = 6.7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ 174.7, 157.6, 152.7, 
152.3, 145.5, 117.8, 110.4, 109.9, 103.9, 97.2, 95.5, 95.1, 74.2, 58.6, 56.6, 56.5, 24.0; IR (film, υ 
cm
-1
): 3397, 1621, 1494, 1460, 1266, 1227, 986; HRMS (ESI) calc. for C17H18NaO7 [M+Na]
+
: 




Following the general procedure for propargyl alcohol formation, iodochromone (25) was 
transformed into propargyl alcohol. The crude material was purified via silica gel column 
chromatography (1:1 hexanes:EtOAc) to give pure propargyl alcohol (696 mg, 2.54 mmol, 84%) 
as an amber oil. 
 
Rf = 0.28 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.16 (dd, J = 7.9, 1.0 
Hz, 1H), 8.09 (s, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.09 (d, J = 1.0 Hz, 1H), 5.27 (s, 2H), 4.79 (q, J = 
6.8 Hz, 1H), 3.50 (s, 3H), 2.43 (bs, 1H), 1.56 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 
δ 175.0, 161.7, 157.8, 157.3, 127.5, 117.8, 115.9, 110.6, 103.1, 97.6, 94.3, 73.9, 58.4, 56.4, 23.9; 
IR (film, υ cm
-1
): 3392, 1624, 1249, 1077; HRMS (ESI) calc. for C15H14NaO5 [M+Na]
+
: 
297.07334, obs. 297.07349. 
 
General Procedure for Ynone Formation 
To a stirred solution of propargyl alcohol (1.0 equiv.) and activated 4.0 Å molecular 
sieves (50% by weight) in CH2Cl2 (0.1 M) at 23 °C was added solid pyridinium dichromate (5.0 
equiv.). After 5 hours, the reaction mixture was filtered through a pad of Celite and concentrated 
in vacuo to give crude ynone. The crude material was purified via silica gel column 







Following the general procedure for ynone formation, propargyl alcohol (tert-butyl 3-(3-
hydroxybut-1-yn-1-yl)-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-
carboxylate) was transformed into ynone (19). The crude material was purified via silica gel 
column chromatography (1:1 hexanes:EtOAc) to give pure ynone (19) (2.79 g, 5.90 mmol, 56%) 
as a white solid (m.p. 182-183 °C). 
 
Rf = 0.41 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.20 (s, 1H), 7.21 (s, 
1H), 5.24 (s, 2H), 3.44 (s, 3H), 2.46 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 
13
C NMR (100 MHz, 
CDCl3): δ 184.2, 175.4, 172.1, 163.1, 160.4, 154.6, 153.7, 136.8, 128.3, 114.6, 108.7, 104.0, 
94.7, 93.5, 83.5, 81.0, 56.7, 39.2, 32.7, 28.2, 27.2; IR (film, υ cm
-1
): 1762, 1734, 1672, 1620, 
1459, 1264, 1246, 1155, 1091; HRMS (ESI) calc. for C25H28NaO9 [M+Na]
+





Following the general procedure for ynone formation, propargyl alcohol (3-(3-hydroxybut-1-
yn-1-yl)-6,7-bis(methoxymethoxy)-4H-chromen-4-one) was transformed into ynone (21). The 
crude material was purified via silica gel column chromatography (5:2:1 
CH2Cl2:EtOAc:hexanes) to give pure ynone (21) (540 mg, 1.63 mmol, 56%) as a white solid 
(m.p. 119-120 °C). 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3): δ 8.23 (s, 1H), 
7.86 (s, 1H), 7.26 (s, 1H), 5.35 (s, 2H), 5.32 (s, 2H), 3.54 (s, 3H), 3.53 (s, 3H), 2.49 (s, 3H); 
13
C 
NMR (100 MHz, CDCl3): δ 184.3, 173.5, 160.7, 153.0, 152.2, 146.0, 117.8, 110.4, 108.1, 104.1, 
95.5, 95.2, 93.4, 81.8, 56.7, 56.5, 32.7; IR (film, υ cm
-1
): 1668, 1640, 1615, 1271, 970; HRMS 
(ESI) calc. for C17H17O7 [M+H]
+




Following the general procedure for ynone formation, propargyl alcohol (3-(3-hydroxybut-1-
yn-1-yl)-7-(methoxymethoxy)-4H-chromen-4-one) was transformed into ynone (22). The 
crude material was purified via silica gel column chromatography (3:1 to 2:1 hexanes:EtOAc) to 
give pure ynone (22) (410 mg, 1.51 mmol, 64%) as a white solid (m.p. 139-141 °C). 
 
Rf = 0.65 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 8.17 (d, J 
= 8.6 Hz, 1H), 7.13 (dd, J = 8.6, 2.4 Hz, 1H), 7.11 (d, J = 2.1 Hz, 1H), 5.28 (s, 2H), 3.50 (s, 3H), 
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2.49 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ 183.9, 173.5, 162.0, 160.9, 157.1, 127.3, 117.6, 
116.3, 108.3, 103.3, 94.2, 93.2, 81.4, 56.3, 32.5; IR (film, υ cm
-1
): 1669, 1632, 1255, 1158; 
HRMS (ESI) calc. for C15H12NaO5 [M+Na]
+





To a stirred solution of ynone (19) (100 mg, 0.212 mmol, 1.0 equiv.) and H2O (3.81 mL, 
212 mmol, 1000 equiv.) in MeCN (21.2 mL, 0.01 M) at 23 °C was added triethylamine (0.3 mL, 
2.12 mmol, 10 equiv.).  After 1 hour, the reaction mixture was diluted with EtOAC (20 mL), 
dried over Na2SO4 and concentrated in vacuo to give aldehyde (20) (104 mg, 0.212 mmol, 99%) 
as an amber solid (m.p. 178-179 °C (decomp.)) of sufficient purity for subsequent reactions. 
 
Rf = 0.23 (silica gel, 1:1 hexanes:EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 10.42 (s, 1H), 7.20 (s, 
1H), 5.23 (s, 2H), 4.26 (bs, 2H), 3.45 (s, 3H), 2.38 (s, 3H), 1.64 (s, 9H), 1.39 (s, 9H); 
13
C NMR 
(125 MHz, CDCl3) δ 200.0, 190.7, 175.4, 175.0, 168.5, 163.3, 154.5, 153.9, 136.7, 128.2, 117.4, 
115.5, 104.1, 94.8, 83.4, 56.6, 47.5, 39.2, 30.4, 28.2, 27.2; IR (film, υ cm
-1
) 3420, 1762, 1730, 





General Procedure A for Ynone Dimerization 
 To a stirred solution of ynone (1.0 equiv.) (intended left side of protected vinaxanthone) 
and H2O (1000 equiv.) in MeCN (0.01 M) at 23 °C was added triethylamine (10 equiv.). After 1 
hour, the reaction mixture was diluted with EtOAc, dried over Na2SO4 and concentrated in vacuo 
to give an amber oil. The crude aldehyde was diluted to 0.1 M with MeCN before ynone (1.0 
equiv.) (intended right side of protected vinaxanthone) and triethylamine (2 equiv.) were added. 
The reaction mixture was stirred at 23 °C for 16 hours. The reaction mixture was then 
concentrated to give crude protected vinaxanthone. The crude material was purified via silica gel 
column chromatography to give pure protected vinaxanthone. 
 
General Procedure B for Ynone Dimerization 
 To a stirred solution of ynone (1.0 equiv.) in MeCN (0.1 M) at 23 °C was added a 1.0 M 
solution of H2O in MeCN (0.5 equiv.) and triethylamine (10 equiv.). After 16 hours, the reaction 
mixture was concentrated in vacuo to give crude protected vinaxanthone. The crude material was 








Following general procedure B for ynone dimerization, ynone (19) was transformed into 
the protected vinaxanthone. The crude material was purified via silica gel column 
chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (85 mg, 
0.090 mmol, 87%) as a white-tan solid (m.p. 224-225 °C). 
 
Rf = 0.68 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.62 (bs, 
1H), 7.84 (bs, 1H), 7.22 (s, 1H), 7.18 (s, 1H), 5.27 (s, 2H), 5.26 (s, 2H), 3.47 (s, 3H), 3.46 (s, 
3H), 2.65 (bs, 3H), 2.41 (bs, 3H), 1.68 (s, 9H), 1.58 (s, 9H), 1.39 (s, 9H), 1.37 (s, 9H); 
13
C NMR 
(125 MHz, CDCl3) δ 201.3, 198.8, 175.4 (2 signals), 173.3 (2 signals), 163.4, 163.3, 155.1, 
154.6, 154.5, 154.0, 153.5, 152.6, 136.4 (2 signals), 135.9, 133.9, 132.3, 128.9, 128.2, 126.8, 
121.2, 120.7, 115.0, 112.7, 103.9, 103.6, 94.7, 94.6, 83.3, 82.8, 56.7, 56.5, 39.2, 39.1, 32.5, 29.6, 
28.1, 28.0, 27.2, 27.1; IR (film, υ cm
-1
) 1763, 1735 1460, 1264, 1157; HRMS (ESI) calc. for 
C50H56NaO18 [M+Na]
+





Following general procedure A for ynone dimerization, ynone (19) and ynone (21) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (37 
mg, 0.046 mmol, 23%) as a yellow solid (m.p. 116-118 °C). A side-product protected 
vinaxanthone (ynone (19) homodimer) (31 mg, 0.047 mmol, 46% with respect to ynone (19)) 
and another side-product protected vinaxanthone (ynone (21) homodimer) (23 mg, 0.024 mmol, 
24% with respect to ynone (21)) were also isolated. 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.67 (bs, 
1H), 7.98 (s, 1H), 7.84 (bs, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 5.39 (s, 2H), 5.35 (s, 2H), 5.26 (s, 
2H), 3.57 (s, 3H), 3.56 (s, 3H), 3.47 (s, 3H), 2.67 (bs, 3H), 2.42 (bs, 3H), 1.58 (s, 9H), 1.37 (s, 
9H); 
13
C NMR (125 MHz, CDCl3) δ 201.8, 199.0, 175.5, 174.5, 173.5, 163.4, 155.2, 154.2, 
153.9, 153.6, 153.1, 152.3, 145.1, 136.4, 134.1, 131.8, 128.2, 126.9, 121.4, 120.6, 115.8, 115.1, 
111.4, 110.5, 103.9, 103.8, 95.7, 95.2, 94.7, 82.8, 56.7, 56.6, 56.5, 39.2, 32.5, 28.9, 28.2, 27.3; 
IR (film, υ cm
-1
) 1654, 1459, 1268, 1156, 1092; HRMS (ESI) calc. for C42H44NaO16 [M+Na]
+
: 





Following general procedure A for ynone dimerization, ynone (19) and ynone (22) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (86 
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mg, 0.115 mmol, 56%) as a pale off-white solid (m.p. 138-139 °C). A side-product protected 
vinaxanthone (ynone (19) homodimer) (22 mg, 0.040 mmol, 39 % with respect to ynone (19)) 
and another side-product protected vinaxanthone (ynone (22) homodimer) (10 mg, 10 µmol, 
10% with respect to ynone (22)) were also isolated. 
 
Rf = 0.65 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (500 MHz, CDCl3) δ 8.64 (bs, 
1H), 8.24 (d, J = 8.8 Hz, 1H), 7.84 (bs, 1H), 7.21 (s, 1H), 7.09 (d, J = 2.3 Hz, 1H), 7.06 (dd, J = 
8.8, 2.3 Hz, 1H), 5.28 (s, 2H), 5.24 (s, 2H), 3.50 (s, 3H), 3.45 (s, 3H), 2.65 (bs, 3H), 2.41 (bs, 
3H), 1.56 (s, 9H), 1.36 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 201.6, 198.8, 175.4, 174.7, 
173.4, 163.3, 163.1, 157.3, 155.1, 153.9, 153.5, 153.1, 136.4, 136.0, 134.1, 132.1, 128.4, 128.1, 
126.9, 121.3, 121.0, 116.2, 115.3, 115.0, 103.9, 103.1, 94.7, 94.4, 82.7, 56.5 (2 signals), 39.1, 
32.4, 28.8, 28.1, 27.2; IR (film, υ cm
-1
) 1620, 1460, 1262, 1158, 1096; HRMS (ESI) calc. for 
C40H40NaO14 [M+Na]
+





Following general procedure A for ynone dimerization, ynone (21) and ynone (19) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone 
(107 mg, 0.140 mmol, 55%) as a yellow solid (m.p. 152-154 °C). A side-product protected 
vinaxanthone (ynone (19) homodimer) (29 mg, 0.031 mmol, 24% with respect to ynone (19)) 
was also isolated. 
 
Rf = 0.49 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 
7.83 (s, 1H), 7.82 (s, 1H), 7.26 (s, 1H), 7.19 (s, 1H), 5.37 (s, 2H), 5.31 (q, J = 4.5 Hz, 2H)*, 5.27 
(q, J = 3.4 Hz, 2H)*, 3.54 (s, 3H), 3.53 (s, 3H), 3.47 (s, 3H), 2.64 (s, 3H), 2.45 (s, 3H), 1.69 (s, 
9H), 1.39 (s, 9H); 
13
C NMR (150 MHz, CDCl3) δ 201.3, 199.3, 175.5, 174.6, 173.4, 163.5, 
154.7, 154.6, 153.9, 152.9, 152.7, 145.6, 136.3, 135.9, 133.9, 133.3, 129.0, 127.4, 122.1, 120.7, 
118.1, 112.8, 110.6, 104.1, 103.9, 103.8, 103.7, 95.6, 95.1, 94.8, 83.3, 56.7, 56.5, 39.2, 32.4, 
28.9, 28.2, 27.3; IR (film, υ cm
-1
) 1458, 1155, 1090; HRMS (ESI) calc. for C42H44NaO16 
[M+Na]
+
: 827.25220, obs. 827.25350. 





Following general procedure B for ynone dimerization, ynone (21) was transformed into 
the protected vinaxanthone. The crude material was purified via silica gel column 
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chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (52 mg, 
0.078 mmol, 52%) as a yellow solid (m.p. 144-146 °C). 
 
Rf = 0.24 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 
7.98 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.26 (s, 1H), 7.23 (s, 1H), 5.38 (d, J = 1.0 Hz, 2H)*, 5.36 
(d, J = 5.1 Hz, 2H)*, 5.32 (d, J = 4.8 Hz, 2H)*, 3.56 (s, 3H), 3.54 (s, 3H), 3.54 (s, 3H), 2.66 (s, 
3H), 2.46 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 201.6, 199.2, 174.7, 174.5, 154.2, 153.8, 
153.1, 152.9 (2 signals), 152.3, 145.6, 145.1, 135.8, 134.1, 132.8, 127.4, 121.2, 120.6, 118.1, 
115.8, 111.4, 110.6, 104.1, 103.8, 95.7, 95.6, 95.2, 95.1, 56.7, 56.5, (3 signals), 32.4, 28.9; IR 
(film, υ cm
-1
) 1618, 1497, 1458, 1269, 1154; HRMS (ESI) calc. for C34H32NaO14 [M+Na]
+
: 
687.16840, obs. 687.16970. 





Following general procedure A for ynone dimerization, ynone (21) and ynone (22) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (71 
mg, 0.117 mmol, 46%) as a yellow solid (m.p. 210-212 °C). A side-product protected 
vinaxanthone (ynone (21) homodimer) (19 mg, 0.035 mmol, 27% with respect to ynone (21)) 
was also isolated. 
 
Rf = 0.35 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 
8.28 (d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 7.81 (s, 1H), 7.26 (s, 1H), 7.11 (s, 1H), 7.08 (d, J = 1.7 Hz, 
1H), 5.37 (s, 2H), 5.31 (d, J = 4.5 Hz, 2H)*, 3.54 (s, 3H), 3.53 (s, 3H), 3.52 (s, 3H), 2.65 (s, 3H), 
2.46 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 201.5, 199.2, 174.8, 174.6, 163.2, 157.4, 153.9, 
153.3, 152.9 (2 signals), 145.6, 136.0, 134.1, 133.1, 128.5, 127.4, 121.1 (2 signals), 118.2, 116.3, 
115.3, 110.6, 104.1, 103.2, 95.6, 95.1, 94.4, 56.5 (3 signals), 32.4, 28.9; IR (film, υ cm
-1
) 1642, 
1621, 1456, 1262, 1155; HRMS (ESI) calc. for C32H28NaO12 [M+Na]
+
: 627.14730, obs. 
627.14770. 





Following general procedure A for ynone dimerization, ynone (22) and ynone (19) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone 
(117 mg, 0.157 mmol, 46%) as a pale yellow solid (m.p. 148-149 °C). A side-product protected 
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vinaxanthone (ynone (19) homodimer) (72 mg, 0.076 mmol, 44% with respect to ynone (19)) 
and another side-product protected vinaxanthone (ynone (22) homodimer) (23 mg, 0.042 mmol, 
25% with respect to ynone (22)) were also isolated. 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 
8.13 (d, J = 8.7 Hz, 1H), 7.82 (s, 1H), 7.19 (s, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.08 (dd, J = 8.7, 
2.4 Hz, 1H), 5.29 (s, 2H), 5.27 (d, J = 3.8 Hz, 2H)*, 3.51 (s, 3H), 3.47 (s, 3H), 2.64 (s, 3H), 2.45 
(s, 3H), 1.69 (s, 9H), 1.39 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 201.2, 199.1, 175.5, 174.9, 
173.3, 163.5, 161.9, 157.9, 154.7, 154.6, 154.1, 152.7, 136.3, 135.9, 133.9, 133.1, 129.0, 127.7, 
127.4, 121.6, 120.7, 118.3, 115.9, 112.7, 103.7, 103.4, 94.8, 94.3, 83.3, 56.7, 56.4, 39.2, 32.4, 
28.9, 28.2, 27.3; IR (film, υ cm
-1
) 1615, 1463, 1252, 1156, 1091; HRMS (ESI) calc. for 
C40H40NaO14 [M+Na]
+
: 767.23103, obs. 767.23034. 





Following general procedure A for ynone dimerization, ynone (22) and ynone (21) were 
transformed into the protected vinaxanthone. The crude material was purified via silica gel 
column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (94 
mg, 0.155 mmol, 45%) as a yellow solid (m.p. 84-85 °C). A side-product protected vinaxanthone 
(ynone (21) homodimer) (3 mg, 5.15 µmol, 52% with respect to ynone (21)) and protected 
vinaxanthone (ynone (22) homodimer) (24 mg, 0.044 mmol, 3% with respect to ynone (22)) 
were also isolated. 
 
Rf = 0.33 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.73 (s, 1H), 
8.13 (d, J = 8.9 Hz, 1H), 7.99 (s, 1H), 7.81 (s, 1H), 7.23 (s, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.08 
(dd, J = 8.9, 2.4, 1H), 5.38 (s, 2H), 5.35 (s, 2H), 5.28 (s, 2H), 3.56 (s, 3H), 3.57 (s, 3H), 3.51 (s, 
3H), 2.66 (s, 3H), 2.46 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 201.6, 199.1, 175.1, 174.5, 
161.9. 158.0, 154.2, 154.0, 153.2, 152.3, 145.1, 135.8, 134.1, 132.6, 127.8, 127.4, 121.7, 120.6, 
118.4, 115.9 (2 signals), 111.4, 103.8, 103.4, 95.7, 95.2, 94.3, 56.7, 56.5, 56.5, 32.4, 28.9; IR 
(film, υ cm
-1
) 1619, 1440, 1270, 1254, 1155; HRMS (ESI) calc. for C32H28NaO12 [M+Na]
+
: 





Following general procedure B for ynone dimerization, ynone (22) was transformed into 
the protected vinaxanthone. The crude material was purified via silica gel column 
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chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone (12 mg, 
0.022 mmol, 24%) as a pale yellow solid (m.p. 215-216 °C). 
 
Rf = 0.50 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 
1
H NMR (400 MHz, CDCl3): δ 8.73 (s, 1H), 
8.29 (d, J = 9.2 Hz, 1H), 8.13 (d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 7.12 (d, J = 2.1 Hz, 1H), 7.11 
(dd, J = 9.2, 2.1 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.09 (dd, J = 8.9, 2.4 Hz, 1H), 5.31 (s, 2H), 
5.29 (s, 2H), 3.52 (s, 3H), 3.51 (s, 3H), 2.66 (s, 3H), 2.47 (s, 3H); 
13
C NMR (100 MHz, CDCl3): 
δ 210.5, 199.1, 175.0, 174.7, 163.1, 161.9, 157.9, 157.3, 154.0, 153.2, 135.8, 134.1, 132.9, 128.4, 
127.7, 127.4, 121.6, 121.0, 118.3, 116.2, 115.8, 115.3, 103.3, 103.2, 94.4, 94.3, 56.5, 56.4, 32.4, 
28.9; IR (film, υ cm
-1
): 1684, 1636, 1483, 1153; HRMS (ESI) calc. for C30H24NaO10 [M+Na]
+
: 
567.12617, obs. 567.12611. 
 
General Procedure A for Protected Vinaxanthone Deprotection 
 To a stirred solution of protected vinaxanthone (1.0 equiv.) in CH2Cl2 at 0 °C was added 
a 1.0 M solution of boron trichloride in CH2Cl2 (2.0 equiv. per protecting group). The reaction 
mixture was stirred at 23 °C for 1 hour. The reaction mixture was then diluted with EtOAc and 
washed with brine (5x). The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give crude vinaxanthone. Trituration with pentane:MeOH (ratio varies depending on substrate 
solubility) gave pure vinaxanthone. 
 
General Procedure B for Protected Vinaxanthone Deprotection 
 A solution of protected vinaxanthone (1.0 equiv.) in 1.25 M methanolic HCl (10 equiv. 
per protected group) was stirred at 65 °C for 8 hrs. The reaction was followed by aliquot 1H 
NMR. The reaction mixture was then purged with N2 and concentrated in vacuo to give crude 
vinaxanthone. Trituration with pentane:MeOH (ratio varies depending on substrate solubility) 




xanthene-1-carboxylic acid (vinaxanthone) (2) 
Following general procedure A for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2) (155 mg, 0.269 mmol, 98%), a yellow 
solid (m.p. 280 °C (decomp.)). 
 
Rf = 0.05 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 12.89 (bs, 1H), 
12.72 (bs, 1H), 11.69 (bs, 1H), 11.44 (bs, 1H), 9.42 (bs, 2H), 8.53 (s, 1H), 8.18 (s, 1H), 6.96 (s, 
1H), 6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 
13
C NMR (125 MHz, (CD3)2SO) δ 201.1, 199.1, 
172.9, 172.6, 167.4, 167.4, 154.1, 152.7, 152.5, 152.1, 150.7, 150.3, 141.7, 141.0, 136.2, 133.4, 
132.6, 126.3, 120.8, 120.5, 119.8, 119.6, 112.4, 110.0, 102.4, 102.3, 32.1, 29.1; IR (KBr, υ cm
-1
) 
3236, 1683, 1653, 1472, 1288; HRMS (ESI) calc. for C28H15O14 [MH]








1-carboxylic acid (2a) 
Following general procedure A for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2a) (9 mg, 0.017 mmol, 97%), a tan solid 
(m.p. 248-250 °C (decomp.)). 
 
Rf = 0.14 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 12.73 (bs, 1H), 
11.47 (bs, 1H), 10.87 (bs, 1H), 9.98 (bs, 1H), 9.44 (bs, 1), 8.57 (s, 1H), 8.17 (s, 1H), 7.48 (s, 1H), 
6.96 (s, 1H), 6.95 (s, 1H), 2.54 (s, 3H), 2.50 (s, 3H); 
13
C NMR (125 MHz, (CD3)2SO) δ 201.2, 
199.2, 173.4, 172.9, 167.4, 154.4, 152.7, 152.6, 152.5, 150.8, 150.7, 144.5, 144.7, 136.1, 133.6, 
132.4, 126.3, 120.9, 119.8, 119.6, 113.5, 112.5, 108.7, 103.1, 102.3, 32.1, 29.1; IR (KBr, υ cm
-1
) 
3219, 1470, 1196, 803; HRMS (ESI) calc. for C27H15O12 [MH]





carboxylic acid (2b) 
Following general procedure A for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2b) (8 mg, 0.015 mmol, 96%), a tan solid 
(m.p. 254-255 °C (decomp.)). 
 
Rf = 0.31 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 12.70 (bs, 1H), 
11.42 (bs, 1H), 11.15 (bs, 1H), 9.42 (bs, 1H), 8.57 (s, 1H), 8.17 (s, 1H), 8.10 (d, J = 8.9 Hz, 1H), 
6.98 (d, J = 8.9 Hz, 1H), 6.96 (s, 1H), 6.92 (s, 1H), 2.56 (s, 3H), 2.54 (s, 3H); 
13
C NMR (125 
MHz, (CD3)2SO) δ 201.1, 199.2, 173.6, 172.8, 167.3, 164.6, 157.2, 152.7, 152.6, 152.5, 150.7, 
141.7, 136.5, 133.6, 132.8, 128.1, 126.2, 120.8, 120.3, 119.6, 114.9, 113.8, 112.4, 102.5, 102.3, 
32.1, 29.2; IR (KBr, υ cm
-1
) 3381, 1618, 1466, 1274; HRMS (ESI) calc. for C27H15O11 [MH]

: 




5-carboxylic acid (2c) 
Following general procedure A for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2c) (5 mg, 8.83 µmol, 89%), a tan solid 
(m.p. 225-226 °C). 
 
Rf = 0.13 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 11.71 (bs, 1H), 
10.59 (bs, 1), 9.92 (bs, 1H), 9.44 (bs, 1H), 8.55 (s, 1H), 8.15 (s, 1H), 7.28 (s, 1H), 6.96 (s, 1H), 
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6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 
13
C NMR (125 MHz, (CD3)2SO) δ 201.0, 199.0, 173.5, 
172.6, 167.3, 154.0, 152.9, 152.8, 152.1, 151.0, 150.2, 144.9, 140.9, 135.9, 133.2, 132.9, 126.4, 
120.6, 120.5, 119.7, 115.7, 110.0, 107.9, 102.9, 102.4, 32.2, 29.1; IR (KBr, υ cm
-1
) 3393, 1624, 
1577, 1466, 1290; HRMS (ESI) calc. for C27H15O12 [MH]






Following general procedure B for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2d) (48 mg, 0.098 mmol, 97%), a 
magenta solid (m.p. 290 °C (decomp.)). 
 
Rf = 0.24 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 10.83 (bs, 1H), 
10.55 (bs, 1H), 9.93 (bs, 2H), 8.58 (s, 1H), 8.12 (s, 1H), 7.49 (s, 1H), 7.28 (s, 1H), 6.94 (s, 1H), 
6.93 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 
13
C NMR (125 MHz, (CD3)2SO) δ 201.1, 199.0, 173.6, 
173.3, 154.3, 152.8 (2 signals), 152.4, 151.0, 150.6, 144.9, 144.5, 139.8, 135.8, 133.5, 132.7, 
162.3, 120.7, 119.7, 115.7, 113.4, 108.6, 107.9, 102.9, 32.2, 29.1; IR (KBr, υ cm
-1
) 3382, 1617, 
1473, 1292; HRMS (ESI) calc. for C26H15O10 [MH]






Following general procedure B for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2e) (5 mg, 10.58 µmol, 91%), a magenta 
solid (m.p. 218-220 °C (decomp.)). 
 
Rf = 0.09 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 11.17 
(bs, 1H), 10.59 (bs, 1H), 9.91 (bs, 1H), 8.58 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 8.6 Hz, 1H), 7.29 
(s, 1H), 6.98 (d, J = 8.6 Hz, 1H), 6.94 (s, 1H), 6.91 (s, 1H), 2.55 (s, 3H), 2.54 (s, 3H); 
13
C NMR 
(125 MHz, (CD3)2SO) δ 201.0, 199.0, 173.5, 164.5, 157.2, 152.9, 152.8, 152.6, 151.1, 144.9, 
136.2, 133.5, 133.2, 128.0, 126.3, 120.6, 120.3, 115.7, 114.9, 113.8, 107.9, 102.9, 102.5, 100.0, 
32.2, 29.1; IR (KBr, υ cm
-1
) 3406, 1617, 1560, 1466, 1273; HRMS (ESI) calc. for C26H15O9 [M-
H]
-




carboxylic acid (2f) 
33 
 
Following general procedure A for protected vinaxanthone deprotection, protected 
vinaxanthone X was transformed into pure vinaxanthone X (20 mg, 0.039 mmol, 96%), a yellow 
solid (m.p. 208-210 °C (decomp.)). 
 
Rf = 0.09 (silica gel, 20:1 EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 11.72 (bs, 1H), 
10.96 (bs, 1H), 9.42 (bs, 1H), 8.58 (s, 1H), 8.19 (s, 1H), 7.91 (d, J = 8.9 Hz, 1H), 6.96 (dd, J = 
8.9, 2.4 Hz, 1H), 6.93 (s, 1H), 6.91 (d, J = 2.4 Hz, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 
13
C NMR 
(125 MHz, (CD3)2SO) δ 201.0, 198.9, 173.8, 172.5, 167.3, 163.0, 157.6, 154.0, 153.2, 152.2, 
150.2, 140.9, 135.6, 133.3, 132.6, 127.2, 126.6, 121.6, 120.5, 119.8, 115.7, 115.4, 110.0, 102.4, 
102.2, 32.2, 29.0; IR (KBr, υ cm
-1
) 3385, 1624, 1459, 1290, 1101; HRMS (ESI) calc. for 
C27H15O11 [MH]






Following general procedure B for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2g) (13 mg, 0.028 mmol, 98%), a 
magenta solid (m.p. 208-210 °C (decomp.)). 
 
Rf = 0.06 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 
1
H NMR (400 MHz, (CD3)2SO) δ 10.97 
bs, 1H), 10.86 (bs, 1H), 9.98 (bs, 1H), 8.62 (s, 1H), 8.19 (s, 1H), 7.91 (d, J = 8.9 Hz, 1H), 7.48 
(s, 1H), 6.96 (d, J = 9.2 Hz, 1H), 6.95 (s, 1H), 6.91 (s, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 
13
C NMR 
(125 MHz, (CD3)2SO) δ 201.2, 199.0, 173.9, 173.3, 163.1, 157.7, 154.4, 153.2, 152.5, 150.7, 
144.5, 135.6, 133.6, 132.4, 127.3, 126.6, 121.7, 119.9, 115.8, 115.4, 113.5, 108.7, 103.1, 102.3, 
32.3, 29.1; IR (KBr, υ cm
-1
) 3299, 1624, 1470, 1295; HRMS (ESI) calc. for C26H15O9 [MH]

: 





Following general procedure B for protected vinaxanthone deprotection, protected 
vinaxanthone was transformed into pure vinaxanthone (2h) (8 mg, 0.018 mmol, 99%), a tan solid 
(m.p. 340 °C (decomp.)). 
 
Rf = 0.16 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 
1
H NMR (500 MHz, (CD3)2SO): δ 11.14 
(s, 1H), 10.93 (s, 1H), 8.61 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 7.2 Hz, 1H), 7.91 (d, J = 7.2 Hz, 
1H), 6.91 (s, 1H), 6.91 (s, 1H), 6.98 (ddd, J = 11, 7.2, 2.0 Hz, 2H), 2.57 (s, 3H), 2.57 (s, 3H); 
13
C 
NMR (125 MHz, (CD3)2SO): δ 201.0, 199.0, 173.9, 173.6, 164.5, 163.1, 157.7, 157.2, 153.3, 
152.8, 136.0, 133.6, 132.9, 128.1, 127.3, 126.6, 121.6, 120.5, 115.8, 115.5, 114.9, 113.8, 102.5, 
102.3, 32.3, 29.1; IR (KBr, υ cm
-1
): 3351, 1619, 1468, 1002; HRMS (ESI) calc. for C26H16NaO8 
[M+Na]
+
: 479.07374, obs. 479.07433. 
